Innovation1 Biotech – Cannabinoid Type 2 and Children’s Eye Health
Andrew Salzman, MD, Chief Science Officer at Innovation1 Biotech, a company that is modifying Schedule 1 molecules and creating drug innovation in the f...
3316 articles
Andrew Salzman, MD, Chief Science Officer at Innovation1 Biotech, a company that is modifying Schedule 1 molecules and creating drug innovation in the f...
Stan Abel, CEO of ProJenX, the company leading the way in the development of targeted therapies to address significant unmet medical needs in degenera...
Larry Edwards, Professor of Medicine, Division of Rheumatology and Clinical Immunology, Program Director and Vice Chairman of the Department of Medicine...
Jamie Weiner, a psychologist and co-founder of Inheriting Wisdom, a consultancy for high-net-worth families discusses his book "The Quest for Legitimacy...
Jan Wehkamp, MD, PhD, Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC di...
Heather Woolery-Lloyd, MD, Director of the Skin of Color Division for the University of Miami Department of Dermatology and Cutaneous Surgery discusses ...
Ari Toumpas shares her transitioning journey and how she worked with a speech-language pathologist to train her voice to follow more stereotypically fem...
Ravi Tayi, MD, MPH, Chief Medical Officer at Endo International, plc, a specialty pharmaceutical company, discusses the alarming results of a recent men...
Maya Ram, Clinical Specialist at Ergotron, makers of ergonomic products, discusses the release of a healthcare ebook that focuses on the health and well...
Anna Lichtenstein, a speech-language pathologist at The Ohio State University Wexner Medical Center discusses gender-affirming voice modification therap...